<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166679">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02154698</url>
  </required_header>
  <id_info>
    <org_study_id>00030500</org_study_id>
    <nct_id>NCT02154698</nct_id>
  </id_info>
  <brief_title>22-gauge ProCore Needle v. Standard 22-gauge (P00030500)</brief_title>
  <official_title>A Multi-center Study Comparing Standard 22-gauge and 22-gauge ProCore Needles for Endobronchial Ultrasound</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cook Endoscopy</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thoraxklinik am Universit√§tsklinikum Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the usefulness of two needles (used for obtaining a
      lung tissue sample : (1) standard 22-gauge, and (2) ProCore 22-gauge) for endobronchial
      ultrasound
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the usefulness of two needles used for obtaining a
      lung tissue sample: (1) standard 22-gauge, and (2) ProCore 22-gauge. Both of these needles
      are used to get biopsies (samples) of lung tissue. The standard needle has one bevel (angled
      side of the needle formed when it is sharpened to make a point), while the ProCore needle
      has 2 bevels. The standard needle is more commonly used and we are doing this study to see
      if the ProCore needle would be more useful.

      The investigator in charge of this study is Dr. Nichole T. Tanner. This study is being done
      at four sites and will involve approximately 200 volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Ease of use of 22-gauge ProCore EBUS needles and the standard 22-gauge needles.</measure>
    <time_frame>Within two weeks from the day of the procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of tumor obtained (measured by cell block and ability to perform mutational analysis)</measure>
    <time_frame>Within two weeks from the day of the procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantity of tissue obtained (measured by number of unstructured fragments)</measure>
    <time_frame>Within two weeks from the day of the procedure</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Quantity of Tissue Obtained</condition>
  <condition>Quality of Tissue Obtained</condition>
  <condition>Ease of Use of 22-gauge ProCore EBUS Needles and the Standard 22-gauge Needles</condition>
  <arm_group>
    <arm_group_label>22-gauge Standard Needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have each node sampled starting with the standard 22G needle on the first pass followed by the ProCore 22G needle on the second pass (for a total of 8 passes)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22-gauge ProCore Needle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will have each node sampled starting with the ProCore 22G on the first pass followed by the standard 22G needle on the second pass (for a total of 8 passes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>22-gauge Standard Needle</intervention_name>
    <description>Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following  subject-sedation and the introduction of an EBUS scope into the airway.</description>
    <arm_group_label>22-gauge Standard Needle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>22-gauge ProCore Needle</intervention_name>
    <description>Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following  subject-sedation and the introduction of an EBUS scope into the airway.</description>
    <arm_group_label>22-gauge ProCore Needle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with known or suspected lung cancer with mediastinal adenopathy as defined
             by a mediastinal lymph node &gt;1 cm in short axis or a normal sized lymph node with
             uptake on FDG-PET scan that is higher than background PET activity.

          2. Participants must be at least 18 years old or older, lack bleeding disorders, and be
             able to provide informed consent. The latter two criteria will be assessed from the
             patient's history and the consenting interview.

        Exclusion Criteria:

          1. Subjects who refuse to participate, or demonstrate inability to give informed consent

          2. Subjects who are less than 18 years of age

          3. Subjects who lack fitness for flexible bronchoscopy as determined by the physician
             performing the bronchoscopy before the procedure

          4. Subjects with suspected sarcoidosis, lymphoma, or metastatic cancer from other sites
             (i.e. those without a known or suspected lung primary)

          5. Subjects on anticoagulation (other than Aspirin) whom cannot have their
             anticoagulation held for the procedure due to other clinical reasons (i.e. recent
             cardiac stent placement).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nichole T Tanner, MD, M.S.C.R</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Argyris Zachariou</last_name>
    <phone>843-792-4557</phone>
    <email>zachario@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kate Taylor</last_name>
    <phone>843-792-2297</phone>
    <email>taylkat@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ricardo Ortiz</last_name>
      <phone>925-917-0160</phone>
      <email>rortiz7@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Oakjones-Burgess</last_name>
      <phone>410-955-5288</phone>
      <email>kfriel2@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lonny Yarmus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Medical School</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Akulian</last_name>
      <email>jason_akulian@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Akulian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Argyris Zachariou</last_name>
      <phone>843-792-4557</phone>
      <email>zachario@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kate Taylor</last_name>
      <phone>843-792-2297</phone>
      <email>taylkat@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nichole T Tanner, MD, M.S.C.R</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Universit√§tsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Herth</last_name>
      <phone>49-6221-396-1200</phone>
      <email>Felix.Herth@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Felix Herth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
